Found and Tirzepatide: How the Telehealth Program Prescribes It

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Welcome to the PlexusDx Education Hub, where we unpack GLP-1 and dual-agonist therapies, weight-management protocols, and the inherited biology behind every metabolic result. Explore the full Peptides & GLP-1 library

What follows is independent editorial analysis. PlexusDx holds no commercial relationship, affiliate arrangement, or paid partnership with Found or its parent company.

Search interest in "Found tirzepatide" usually comes from people trying to understand how a subscription telehealth service handles the dual-agonist compound behind Mounjaro and Zepbound. This review looks specifically at the tirzepatide angle: how a program like Found evaluates, prescribes, and fills it, and one biological factor the intake form leaves out. It is fair-balance commentary current as of April 2026, not a purchase recommendation.

What tirzepatide is, in plain terms

Tirzepatide is a synthetic peptide that switches on two gut-hormone receptors at the same time — the GLP-1 receptor and the GIP receptor. Because it engages both incretin pathways rather than one, clinicians describe it as a dual agonist, and that is the mechanistic reason it behaves differently from earlier single-target agents.

The dual-agonist mechanism

GLP-1 signaling slows gastric emptying and dampens appetite, while GIP signaling adds a second lever on insulin secretion and fat metabolism. Stacking the two is the pharmacological idea behind the compound; the everyday effect people report is reduced hunger and earlier fullness.

Branded versus compounded supply

The same active peptide reaches patients two ways. FDA-approved branded versions are dispensed by retail pharmacies, while a 503A compounding pharmacy can prepare a compounded formulation when clinically appropriate. A telehealth program routes to one or the other depending on eligibility, supply, and the prescriber's judgment.

How Found fits a tirzepatide prescription into telehealth

Subscription telehealth compresses the traditional office visit into an online flow. In broad strokes, a prospective patient completes a health questionnaire covering weight, history, and current medications; a licensed clinician reviews it and, when criteria are satisfied, writes a prescription; that order is directed to either a retail or a compounding pharmacy; and follow-up visits handle titration and side-effect check-ins. Found operates inside this general pattern, though provider type, pharmacy partner, and plan tiers differ program to program. Its own site — joinfound.com — is the authoritative source for current structure.

What tirzepatide tends to cost through a subscription

Found lists its own prices, and they shift over time, so the brand's website is where any figure should be confirmed. Across the telehealth GLP-1 market as of April 2026, total monthly outlay commonly lands somewhere between roughly $200 and $700 or more, with wide spread driven by the compound chosen, the subscription tier, and whether the medication is branded or compounded. For comparison on the PlexusDx side, Tirzepatide Injection is offered at $289 per month through the Weight Management Protocols.

What the clinical trials actually measured

Any credible GLP-1 or dual-agonist program leans on the same evidence base. The SURMOUNT program studied tirzepatide for weight management and appeared in The New England Journal of Medicine in 2022, and SURMOUNT-OSA extended that work to obstructive sleep apnea in NEJM in 2024. Semaglutide's STEP program, published in the same journal in 2021, sits alongside them. Enrollment criteria and endpoints differ between studies, and individual outcomes vary.

The genetic layer a tirzepatide script never reads

A telehealth prescription treats the compound as the whole story, but it says nothing about the inherited biology the drug acts upon. FTO, the fat-mass and obesity-associated gene, and MC4R, a melanocortin receptor tied to satiety and energy balance, help set your baseline appetite terrain. GLP1R encodes the very receptor a GLP-1 agonist targets, and TCF7L2 influences glucose handling and incretin secretion. These are pathway-level variants: they do not forecast how you will respond to tirzepatide, but they describe the metabolic ground a clinician is prescribing into. That is exactly the context PlexusDx built its testing around. The Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights — including the FTO, GLP1R, MC4R, and TCF7L2 variants that shape appetite regulation and energy balance — so a protocol decision starts with data instead of guesswork.

How PlexusDx frames the tirzepatide pathway

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols, available as Tirzepatide Injection, Tirzepatide Oral, Semaglutide Injection, and Semaglutide Oral. The distinguishing move is sequence: read the genetics first, then discuss a protocol. That "test before you invest" order turns an open-ended prescription into an informed conversation with your own healthcare provider.

Not affiliated: PlexusDx has no commercial relationship with Found and offers its own compounded protocols independently through licensed 503A pharmacies.

Related reading on PlexusDx: Mounjaro vs Liraglutide, Hers Mounjaro, Hims Mounjaro, Ro Mounjaro.

Frequently Asked Questions

Does Found prescribe branded or compounded tirzepatide?

That depends on eligibility and supply at the time of your visit. Telehealth programs can route a tirzepatide prescription to a retail pharmacy for an FDA-approved branded product or to a 503A compounding pharmacy for a compounded version. Confirm which pathway applies directly on Found's own website before enrolling.

Is compounded tirzepatide the same as the branded drug?

The active peptide is the same molecule, but compounded and branded products differ in manufacturing oversight, formulation, and labeling. Compounded versions are prepared by 503A pharmacies for specific patients. Neither is inherently better for everyone; the right choice is a clinical decision made with a licensed prescriber who knows your history.

Will the Precision Peptide Genetic Test tell me how tirzepatide will work for me?

No. The test never predicts response to tirzepatide or any specific medication. It maps pathway-level variants such as FTO, GLP1R, MC4R, and TCF7L2 that describe your baseline appetite and glucose biology — useful upstream context you and your provider can weigh before choosing any GLP-1 or dual-agonist protocol.

How does PlexusDx pricing for tirzepatide compare?

PlexusDx lists Tirzepatide Injection at $289 per month within its Weight Management Protocols, while Found publishes its own pricing that varies by tier and compound. Beyond the number, the PlexusDx difference is the genetic groundwork offered alongside the protocol rather than a prescription in isolation.

Compare the approach directly: review the Weight Management Protocols for semaglutide and tirzepatide, or begin upstream with the Precision Peptide Genetic Test. This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education

Disclaimer: This review is educational and independent. PlexusDx is not affiliated with Found and holds no commercial relationship with the companies discussed. PlexusDx provides semaglutide and tirzepatide through its own Weight Management Protocols; this piece compares approaches within the GLP-1 telehealth category. The Precision Peptide Genetic Test examines how your genes influence peptide-related biological pathways and does not predict response to any specific medication. Speak with a qualified healthcare provider before starting any peptide protocol.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.